April 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline
 

Tokyo, Apr 8, 2006 (JCN) - Kissei Pharmaceutical announced on April 6 that it has concluded a licensing agreement with GlaxoSmithKline (GSK) for KGA, Kissei Pharmaceutical's proprietary candidate compound for diabetes drug.

Under the agreement terms, GSK will be able to exclusively develop and market the agent worldwide except in Japan, Korea, China and Taiwan, in exchange for making an upfront payment, milestone payments on product development, and royalties on future sales to Kissei Pharmaceutical.

KGA is a selective inhibitor for SGLT1 (sodium-dependent glucose transport 1) which inhibits intestinal sugar absorption and improves postprandial hyperglycemia. Currently, Kissei Pharmaceutical undertakes nonclinical studies of the agent. Going forward, GSK will proceed with clinical studies abroad.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Kissei Pharmaceutical  News  
  Kissei Announces New Drug Application for Silodosin has been Filed with FDA  (Feb 13, 2008)
  Kissei Enters Partners with Pneuma Partners LLC on Calfactant  (Jan 15, 2008)
  Kissei and Eisai Sign License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in China  (Sept 28, 2007)
  Kissei, Nuon Therapeutics Enter Agreement on Transilast  (Aug 1, 2007)
  Kissei and Eisai Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries  (June 12, 2007)
  Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug  (May 11, 2006)
  Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline  (Apr 8, 2006)
  Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug  (Jan 24, 2006)
  Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent  (Dec 27, 2005)
  Kissei Pharmaceutical, Dainippon Pharmaceutical Conclude Licensing Agreement for KGA-2727 Diabetes Drug Candidate  (Mar 17, 2005)


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)